Join our community!

We believe in entrepreneurship in Haifa, and invite you to share a part of our journey


Get listed

Service provider?

Join us today

Have an Event?

Submit an event

Stay updated with our news! our newsletter now


Join our newsletter to be updated
on everything that happens in
entrepreneurship field in Haifa

Promise not to send spam!
You can unsubscribe any time

Home / Startups / VESSL Therapeutics
VESSL Therapeutics

VESSL Therapeutics

Regenerative Medicine for Cardiovascular Diseases

VESSL Therapeutics develops cell-based therapies for patients who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities. Its core technology is based on an integrative approach for the treatment of cardiovascular disease.

VESSLs two leading products, MultiGeneAngio and MultiGeneGraft, have been approved by the FDA for clinical studies, and two phase 1/2 clinical trials with MultiGeneAngio have been completed.

MultiGeneAngio is a combination of two cell types and two genes, and MultiGeneGraft is the combination of cells, genes, and a synthetic graft. These two technologies are used in therapies for patients with peripheral artery disease and coronary artery disease, and for patients with renal disease requiring hemodialysis.

The companys products are based on the patients own cells, isolated from a short vein segment taken from the patients arm under local anesthesia. The isolated cells are activated by the insertion of specific genes and then reintroduced to the patient.

The FDA has granted an Investigational New Drug (IND) authorization for MultiGeneGraft.

Sectors: Pharmaceuticals

Year of establishment:


Fundraising stage:

Revenue Financed

Product/Service stage:

Clinical trial

Number of employees:

Names and roles of the founders:
Moshe Flugelman - Prof., MD, Founder & CEOBasil Levis - MD, Co-FounderElad Tamir - Co-Founder & Board Director

Contact VESSL Therapeutics


Michal 7, Haifa

Phone Number

Want some more?